# US 2019/0315857 A1 · Treatment of peripheral t cell lymphoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315857 A1
- Document ID: US20190315857A1
- Status: Published application
- Kind: A1
- Application number: 16/451,051
- Filed: 2019-06-25
- Published: 2019-10-17
- Earliest claimed: 2013-02-14
- Assignees: Innate Pharma
- Applicants: Innate Pharma
- Inventors: CÉCILE BONNAFOUS; HÉLÈNE SICARD; RENAUD BUFFET; MATHIEU BLERY
- Web page: https://patentgrep.com/patent/US20190315857A1

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- A61P 35/02: specific for leukemia
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/3061: {Blood cells}
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- G01N 2333/70503: Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.

## Claims

### Claim 1

A method for treating a peripheral T cell lymphoma (PTCL) in an individual, the method comprising administering to an individual a therapeutically active amount of a compound that binds an NKp46 polypeptide and depletes NKp46-expressing tumor cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein the individual has an orthovisceral extranodal PTCL.

### Claim 3 (depends on 2)

The method of claim 2, wherein the orthovisceral extranodal disease is NK/T-lymphoma.

### Claim 4 (depends on 2)

The method of claim 2, wherein the orthovisceral extranodal disease is enteropathy associated T cell lymphoma (EATL).

### Claim 5 (depends on 1)

The method of claim 1, wherein the individual has refractory celiac disease (RCD).

### Claim 6 (depends on 1)

The method of claim 1, wherein the PTCL is NK/T lymphoma, nasal type, and wherein the method does not require a step of determining the NKp46 polypeptide status of malignant cells within the individual prior to administration of a compound that binds an NKp46 polypeptide.

### Claim 7 (depends on 1)

The method of claim 1, wherein the treatment of a PTCL in an individual comprises:
a) determining the NKp46 polypeptide status of malignant cells within the individual having a PTCL, and
b) upon a determination that the individual has an NKp46 polypeptide prominently expressed on the surface of malignant cells, administering to the individual said compound that binds an NKp46 polypeptide.

### Claim 8 (depends on 1)

The method of claim 1, wherein the compound that binds an NKp46 polypeptide is an anti-NKp46 antibody.

### Claim 9 (depends on 1)

The method of claim 1, wherein the antibody comprises an amino acid modification that enhances binding to a human Fcγ receptor.

### Claim 10 (depends on 1)

The method of claim 1, wherein the antibody is linked to a toxic agent.

### Claim 11

A method for detecting in an individual a peripheral T cell lymphoma (PTCL) selected from the group consisting of NK/T-lymphoma, enteropathy associated T cell lymphoma (EATL) and refractory celiac disease (RCD) susceptible to progressing to EATL, the method comprising detecting an NKp46 nucleic acid or polypeptide in a biological sample from an individual.

### Claim 12 (depends on 11)

The method of claim 11, wherein detecting an NKp46 polypeptide in a biological sample comprises detecting NKp46 polypeptide expressed on the surface of a malignant lymphocyte.

### Claim 13 (depends on 11)

The method of claim 11, wherein an NKp46 polypeptide is detected, and wherein said detecting an NKp46 polypeptide comprises obtaining a biological sample from the individual that comprises NK/T-lymphoma cells, EATL cells or refractory celiac disease cells, bringing said cells into contact with an antibody that binds an NKp46 polypeptide, and detecting whether cells express NKp46 on their surface.

### Claim 14 (depends on 11)

The method of claim 11, wherein the individual has NK/T-lymphoma.

### Claim 15 (depends on 11)

The method of claim 11, wherein the individual has EATL.

### Claim 16 (depends on 11)

The method of claim 11, wherein the individual has RCD.
